VivoSeq
Other

Bone Pain

14

Pipeline Programs↗

4

Active Trials↗

9

Companies Involved↗

Bone pain is an emerging landscape with 14 programs across 9 companies. The most active players are Amgen, Dexcel Pharma Technologies Ltd., Sorrento Therapeutics, Inc.. 1 therapy is approved with 5 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

42/100

Pipeline Velocity

15/100

Mech. Concentration

14/100

Completion Rate

64/100

Attrition Rate

25/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Amgen logo

Amgen

1 program

Phase 1D

Dexcel Pharma Technologies Ltd.

1 program

Phase 2S

Sorrento Therapeutics, Inc.

1 program

Phase 2Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals

1 program

Phase 3Johnson & Johnson logo

Johnson & Johnson

1 program

Phase 3Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

94%

Small molecule

15 of 16 classified programs — the dominant modality here.

6%ALL OTHERSProtein / enzyme16%

Small molecule leads; the ring shows all 16 classified programs, each share of the total. Modality classified for 100% of 16 pipeline programs.

Analysis

Trial Status

16

clinical trials

Completed7 · 44%
Terminated4 · 25%
Recruiting2 · 13%
Not yet recruiting2 · 13%
Unknown status1 · 6%

Clinical Trials

Trial Activity

16 trials

Samarium Optimized for Long-lasting Analgesia in Cancerous End-stage Bone Pain
Recruiting·TTelix Pharmaceuticals (Innovations) Pty Limited·Phase 1·NCT07197645·33 enrolled
Loratadine for the Prevention of G-CSF-related Bone Pain
Recruiting·AAHS Cancer Control Alberta·Phase 2·NCT05421416·78 enrolled
Non Steroidal Anti-inflammatory Drugs in the Prevention of Bone Pain Flares After Palliative Radiotherapy
Not yet recruiting·—·Phase 2·NCT06903585·385 enrolled
Periganglionic Resiniferatoxin for the Treatment of Intractable Pain Due to Cancer-induced Bone Pain
Not yet recruiting·National Institute of Neurological Disorders and Stroke (NINDS)·Phase 1/2·NCT02522611·30 enrolled
G-CSF-Induced Bone Pain and Supportive Care Approaches
Completed·—·N/A·NCT07192770·225 enrolled
Single-Dose Local Radiation Therapy Compared With Ibandronate in Treating Patients With Localized Metastatic Bone Pain
Completed·CCancer Research UK·Phase 3·NCT00082927·580 enrolled
Atorvastatin (Lipitor) to Prevent Bone Pain
Completed·—·N/A·NCT00120133·12 enrolled
Prevention of Pegfilgrastim-Induced Bone Pain (PIBP)
Completed·—·Phase 3·NCT00602420·510 enrolled
Evaluation of Loratadine for G-CSF Induced Bone Pain in Patients With Hematologic Malignancies
Completed·WWake Forest University Health Sciences·N/A·NCT02305979·61 enrolled
SarCaBon: A Randomised Phase II Trial of Saracatinib Versus Placebo for Cancer-induced Bone Pain
Completed·SSheffield Teaching Hospitals NHS Foundation Trust·Phase 2·NCT02085603·12 enrolled
Novel Preventive Approach Against Filgrastim-Induced Bone Pain in Cancer Patients
Completed·—·Phase 1/2·NCT06265077·58 enrolled
A Study To Evaluate Pregabalin In The Treatment Of Moderate To Severe Chronic Bone Pain Related To Metastatic Cancer
Terminated·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 4·NCT00381095·152 enrolled
Loratadine for Improvement of Bone Pain in Patients With Chronic Granulocyte-Colony Stimulating Factor (G-CSF) Use
Terminated·UUniversity of Michigan·Phase 2·NCT03883386·3 enrolled
Trial of Pregabalin for Granulocyte Colony-stimulating Factor (GCSF)-Induced Bone Pain
Terminated·UUNC Lineberger Comprehensive Cancer Center·Phase 2·NCT03407430·11 enrolled
Study of Loratadine for Pegfilgrastim Induced Bone Pain in Patients With Aggressive Lymphoma
Terminated·MM.D. Anderson Cancer Center·Phase 1·NCT02392039·1 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)